The cost of GLP-1 drugs is a hot topic: the federal government announced last week that it has reached a deal with pharmaceutical companies to lower the cost of GLP-1 drugs, but it remains unclear exactly how this will affect patients
Lastly, we present considerations to accurately interpret these data and outline key knowledge gaps for further investigation
This distinction is especially important for patients who receive medication through telehealth platforms that utilize compounding pharmacies
While the mechanisms responsible for these potent effects remain incompletely understood, contributors include altered postprandial nutrient delivery to the intestine, increased secretion of glucagon-like peptide 1 (GLP-1) by intestinal L cells, increased insulin secretion, intestinal mucosal adaptations, alterations in the gut-brain axis, and changes in bile acid content and composition (3, 4)
Tirzepatide's longer track record in real patients provides greater confidence in its safety profile